Company research
Turn Therapeutics Inc.
CIK 2023016Updated Sep 24, 2026
SecurityTTRX · NASDAQ · equity
Name history
Global Health Solutions, Inc · through Sep 30, 2025
TTRX price & chart
Loading TradingView…
NASDAQ:TTRX on TradingView ↗About the company
We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA-cleared medical devices.
In the news
No coverage from other publishers is available.
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
D filing
Unregistered Sales of Equity Securities
Items 3.02
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 12,162,241Source | 2,048,889Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 922,171Source | 821,931Source |
| Current assets: | ||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,027,862Source | 498,286Source |
| Assets, CurrentUSD | 5,196,444Source | 1,097,924Source |
| Prepaid Expense and Other Assets, CurrentUSD | 120,300Source | 225,325Source |
| Operating Lease, Right-of-Use AssetUSD | 78,620Source | 120,452Source |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 7,475,518Source | 2,226,321Source |
| Stockholders’ equity: | ||
| Common Stock, Value, IssuedUSD | 2,943Source | 2,684Source |
| Retained Earnings (Accumulated Deficit)USD | -22,390,093Source | -19,196,013Source |
| Stockholders' Equity Attributable to ParentUSD | 4,686,723Source | -177,432Source |
| Additional Paid in Capital, Common StockUSD | 28,143,873Source | 19,015,897Source |
| Liabilities and EquityUSD | 12,162,241Source | 2,048,889Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 6,003,424Source | 707,932Source |
| Operating Lease, Liability, CurrentUSD | 46,295Source | 40,660Source |
| Operating Lease, Liability, NoncurrentUSD | 34,081Source | 80,376Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 419,245Source | 352,833Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -2,562,901Source | -1,361,305Source |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -152,986Source | -99,475Source |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,919,432Source | 1,152,382Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 5,076,144Source | 872,599Source |
| Additional Financial Items | ||
| Share-based Payment Arrangement, ExpenseUSD | 320,000Source | 350,000Source |
| Amortization of Deferred ChargesUSD | 500,000Source | — |
| Amortization of Intangible AssetsUSD | 53,000Source | 47,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | 2,574,971Source | — |
| General and Administrative ExpenseUSD | 5,593,078Source | 1,551,168Source |
| Investment Income, InterestUSD | 29,583Source | 28,709Source |
| Net Income (Loss) Attributable to ParentUSD | -3,194,080Source | -1,768,415Source |
| Nonoperating Income (Expense)USD | 2,664,568Source | 28,709Source |
| Operating ExpensesUSD | 5,858,648Source | 1,797,124Source |
| Other Nonoperating Income (Expense)USD | 176,520Source | — |
| Proceeds from Contributed CapitalUSD | 4,070,000Source | — |
| Proceeds from Issuance of Common StockUSD | 6,919,432Source | 1,152,382Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Operating Income (Loss)USD | -5,858,648Source | -1,797,124Source |
| Other Nonoperating Income (Expense)USD | 176,520Source | — |
| Net Income (Loss) Attributable to ParentUSD | -3,194,080Source | -1,768,415Source |
| Earnings Per Share, BasicUSD per share | -0.12Source | -0.07Source |
| Earnings Per Share, DilutedUSD per share | -0.12Source | -0.07Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 27,716,045Source | 26,643,432Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 27,716,045Source | 26,643,432Source |
| Additional Financial Items | ||
| Amortization of Intangible AssetsUSD | 53,000Source | 47,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 52,746Source | 47,483Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | 2,574,971Source | — |
| General and Administrative ExpenseUSD | 5,593,078Source | 1,551,168Source |
| Investment Income, InterestUSD | 29,583Source | 28,709Source |
| Nonoperating Income (Expense)USD | 2,664,568Source | 28,709Source |
| Operating ExpensesUSD | 5,858,648Source | 1,797,124Source |
| Other ExpensesUSD | 1,340,138Source | 866,984Source |
| Research and Development ExpenseUSD | 265,570Source | 245,956Source |
Offerings
Registration 333-290800
Registration 333-289972
- Deal price
- 11.65
- Offering price
- $11.65
- Ticker
- TTRX
Filing attachments
ea030503701ex99-1.htm · 8-K · 2026-09-10
EX-99.1 2 ea030503701ex99-1.htm PRESS RELEASE, DATED SEPTEMBER 10, 2026 Exhibit 99.1 Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum Westlake Village, Calif. - September 10, 2026 - Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory L…
Read attachment ↗ea030480601ex99-1.htm · 8-K · 2026-09-09
EX-99.1 2 ea030480601ex99-1.htm PRESS RELEASE, DATED SEPTEMBER 9, 2026 Exhibit 99.1 Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer Brings internationally recognized expertise in immunology, cytokine biology, host-microbe interactions and public health Westlake Village, Calif. - September 9, 2026 - Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory a…
Read attachment ↗ea030177201ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 ea030177201ex99-1.htm PRESS RELEASE, DATED AUGUST 12, 2026 Exhibit 99.1 Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead First Peer-Reviewed Pu…
Read attachment ↗ea029941301ex99-1.htm · 8-K · 2026-07-28
EX-99.1 2 ea029941301ex99-1.htm INVESTOR PRESENTATION, DATED JULY 28, 2026 Exhibit 99.1 Corporate Presentation July 2026 2 Forward-Looking Statements & Safe Harbour Except for historical information set forth herein, the matters set forth in this presentation contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "may," "might," "will," "s…
Read attachment ↗ea029706101ex99-1.htm · 8-K · 2026-07-07
EX-99.1 2 ea029706101ex99-1.htm PRESS RELEASE, DATED JULY 7. 2026 Exhibit 99.1 Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) Comprehensive interim r…
Read attachment ↗ea029706101ex99-2.htm · 8-K · 2026-07-07
EX-99.2 3 ea029706101ex99-2.htm INVESTOR PRESENTATION, DATED JULY 7, 2026 Exhibit 99.2 GX-03: Phase 2, Stage 2 Overview & Additional Interim Analysis Insights Investor Webcast Presentation July 7, 2026 2 Disclaimers & Safe Harbour Except for historical information set forth herein, the matters set forth in this presentation contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statem…
Read attachment ↗